Measurement of serum prolactin should be performed only when clinically indicated
Normal prolactin levels are less than 25 μg/L in females and less than 20 μg/L in males.1 Measurement is indicated for erectile or ejaculatory dysfunction, amenorrhea, oligomenorrhea, infertility, low libido, or galactorrhea outside pregnancy or nursing.1 The prevalence of hyperprolactinemia in adult populations ranges from 0.4% to 17% in people with amenorrhea, oligomenorrhea, or abnormal uterine bleeding.2 Causes of hyperprolactinemia include macroprolactinemia, pregnancy, medications (dopaminergic antagonists, neuroleptics, antiemetics), untreated primary hypothyroidism, liver failure, renal failure, and hypothalamic or pituitary diseases.1
Mild asymptomatic hyperprolactinemia (20–200 μg/L) is common and often spurious
People with asymptomatic, mild hyperprolactinemia should undergo repeat prolactin measurement in 2–4 weeks, testing for macroprolactin, and testing to exclude pregnancy with a serum β human chorionic gonadotropin.1,3 Macroprolactinemia results from a larger biologically inactive isoform of prolactin that causes mild hyperprolactinemia but is not clinically important; detection may prevent further unnecessary investigations.1 Neuroimaging for asymptomatic patients should be avoided, to reduce unnecessary health care costs and burden of incidental or clinically insignificant findings.4 Appendix 1 (available at www.cmaj.ca/lookup/doi/10.1503/cmaj.241710/tab-related-content) shows an algorithm for the workup of hyperprolactinemia.
Antipsychotic medication can cause marked prolactin elevation
Symptomatic hyperprolactinemia is commonly associated with use of antipsychotics (incidence of 18%–93%).5 First-generation antipsychotics, as well as risperidone, paliperidone, and amisulpride, can cause elevation in prolactin (> 100 μg/L).1 Some second-generation antipsychotics cause milder hyperprolactinemia (< 100 μg/L).1 Hyperprolactinemia secondary to antipsychotic use is often indiscernible from other causes; consultation with an endocrinology specialist for workup and management is appropriate.
Marked hyperprolactinemia (> 200 μg/L) in the absence of interfering medications is suggestive of prolactinoma
This scenario should prompt further evaluation for hypopituitarism and visual dysfunction with referral to an endocrinology specialist.1,3 Prolactinomas are associated with hyperprolactinemia proportional to size (i.e., 100–200 μg/L for < 1 cm, to > 10 000 μg/L for > 3 cm).1,3
Hyperprolactinemia accompanied by visual dysfunction (extraocular movement dysfunction, field deficit, or decreased acuity) is an indication for urgent neuroimaging and assessment by an ophthalmologist
Although gadolinium-enhanced magnetic resonance imaging (MRI) of the sella is gold standard,1 contrast-enhanced computed tomography of the sella is appropriate if MRI is not immediately available. A pituitary macroadenoma contacting the optic chiasm requires urgent consultation with endocrinology and neurosurgery specialists.
CMAJ invites submissions to “Five things to know about …” Submit manuscripts online at https://mc.manuscriptcentral.com/cmaj.
Supplementary Information
Footnotes
Competing interests: Kirstie Lithgow reports receiving support from the Canadian Society for Endocrinology and Metabolism for travel to the 2024 annual meeting, and honoraria for presenting a continuing medical education event at the symposium, which was sponsored by NovoNordisk. No other competing interests were declared.
This article has been peer reviewed.
References
- 1.Samperi I, Lithgow K, Karavitaki N. Hyperprolactinaemia. J Clin Med 2019;8:2203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lee D-Y, Oh Y-K, Yoon B-K, et al. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol 2012;206:213.e1–5. [DOI] [PubMed] [Google Scholar]
- 3.Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 2023;19:722–40. [DOI] [PubMed] [Google Scholar]
- 4.Hamblin R, Fountas A, Lithgow K, et al. Natural history of non-functioning pituitary microadenomas: results from the UK nonfunctioning pituitary adenoma consortium. Eur J Endocrinol 2023;189:87–95. [DOI] [PubMed] [Google Scholar]
- 5.Jiang Q, Li T, Zhao L, et al. Treatment of antipsychotic-induced hyperprolactinemia: an umbrella review of systematic reviews and meta-analyses. Front Psychiatry 2024;15:1337274. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
